Organogenesis Hldgs Analyst Ratings
Organogenesis Hldgs Analyst Ratings
While ratings are subjective and will change, the latest Organogenesis Hldgs (ORGO) rating was a maintained with a price target of $3.00 to $3.50. The current price Organogenesis Hldgs (ORGO) is trading at is $2.35, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 48.94% | Morgan Stanley | $3 → $3.5 | Maintains | Equal-Weight |
| 08/11/2023 | 27.66% | Morgan Stanley | $5 → $3 | Maintains | Equal-Weight |
| 08/10/2023 | 70.21% | BTIG | $10 → $4 | Maintains | Buy |
| 06/15/2023 | 112.77% | Morgan Stanley | → $5 | Initiates Coverage On | → Equal-Weight |
| 05/24/2023 | 325.53% | BTIG | → $10 | Upgrades | Neutral → Buy |
| 11/10/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 11/10/2021 | 751.06% | SVB Leerink | $26 → $20 | Maintains | Outperform |
| 08/10/2021 | 963.83% | Credit Suisse | $24 → $25 | Maintains | Outperform |
| 05/11/2021 | 1006.38% | SVB Leerink | $27 → $26 | Maintains | Outperform |
| 03/17/2021 | 836.17% | SVB Leerink | $19 → $22 | Maintains | Outperform |
| 01/20/2021 | 453.19% | SVB Leerink | $10 → $13 | Maintains | Outperform |
| 01/07/2021 | 282.98% | Credit Suisse | $8 → $9 | Maintains | Outperform |
| 11/18/2020 | 325.53% | SVB Leerink | $9 → $10 | Maintains | Outperform |
| 11/10/2020 | 240.43% | Credit Suisse | $7 → $8 | Maintains | Outperform |
| 08/11/2020 | 282.98% | SVB Leerink | $7 → $9 | Maintains | Outperform |
| 05/12/2020 | 197.87% | SVB Leerink | $8 → $7 | Maintains | Outperform |
| 04/09/2020 | 240.43% | BTIG | $9 → $8 | Maintains | Buy |
| 01/10/2020 | 282.98% | SVB Leerink | → $9 | Initiates Coverage On | → Outperform |
| 08/26/2019 | — | Credit Suisse | Reinstates | → Outperform | |
| 05/02/2019 | 282.98% | Credit Suisse | → $9 | Initiates Coverage On | → Outperform |
| 04/17/2019 | 368.09% | Oppenheimer | → $11 | Initiates Coverage On | → Outperform |
| 04/12/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 04/11/2019 | 368.09% | SunTrust Robinson Humphrey | → $11 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/14/2023 | 48.94% | 摩根士丹利 | 3 美元 → 3.5 美元 | 維護 | 重量相等 |
| 08/11/2023 | 27.66% | 摩根士丹利 | 5 美元 → 3 美元 | 維護 | 重量相等 |
| 08/10/2023 | 70.21% | BTIG | 10 美元 → 4 美元 | 維護 | 買 |
| 06/15/2023 | 112.77% | 摩根士丹利 | → 5 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 05/24/2023 | 325.53% | BTIG | → 10 美元 | 升級 | 中性 → 買入 |
| 2022 年 10 月 11 日 | — | BTIG | 降級 | 買入 → 中性 | |
| 11/10/2021 | 751.06% | SVB Leerink | 26 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 08/10/2021 | 963.83% | 瑞士信貸 | 24 美元 → 25 美元 | 維護 | 跑贏大盤 |
| 05/11/2021 | 1006.38% | SVB Leerink | 27 美元 → 26 美元 | 維護 | 跑贏大盤 |
| 03/17/2021 | 836.17% | SVB Leerink | 19 美元 → 22 美元 | 維護 | 跑贏大盤 |
| 2021 年 1 月 20 日 | 453.19% | SVB Leerink | 10 美元 → 13 美元 | 維護 | 跑贏大盤 |
| 01/07/2021 | 282.98% | 瑞士信貸 | 8 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 2020 年 11 月 18 日 | 325.53% | SVB Leerink | 9 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 11/10/2020 | 240.43% | 瑞士信貸 | 7 美元 → 8 美元 | 維護 | 跑贏大盤 |
| 08/11/2020 | 282.98% | SVB Leerink | 7 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 05/12/2020 | 197.87% | SVB Leerink | 8 美元 → 7 美元 | 維護 | 跑贏大盤 |
| 04/09/2020 | 240.43% | BTIG | 9 美元 → 8 美元 | 維護 | 買 |
| 2020 年 10 月 1 日 | 282.98% | SVB Leerink | → 9 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 08/26/2019 | — | 瑞士信貸 | 恢復 | → 跑贏大盤 | |
| 2019 年 2 月 5 日 | 282.98% | 瑞士信貸 | → 9 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 04/17/2019 | 368.09% | 奧本海默 | → 11 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2019 年 12 月 4 日 | — | BTIG | 啓動覆蓋範圍開啓 | → 購買 | |
| 04/11/2019 | 368.09% | SunTrust 羅賓遜·漢弗萊 | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Organogenesis Hldgs (ORGO)?
Organogenesis Hldgs（ORGO）的目標價格是多少？
The latest price target for Organogenesis Hldgs (NASDAQ: ORGO) was reported by Morgan Stanley on November 14, 2023. The analyst firm set a price target for $3.50 expecting ORGO to rise to within 12 months (a possible 48.94% upside). 5 analyst firms have reported ratings in the last year.
摩根士丹利於2023年11月14日公佈了Organogenesis Hldgs（納斯達克股票代碼：ORGO）的最新目標股價。該分析公司將目標股價定爲3.50美元，預計ORGO將在12個月內升至12個月內（可能上漲48.94％）。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Organogenesis Hldgs (ORGO)?
分析師對Organogenesis Hldgs（ORGO）的最新評級是多少？
The latest analyst rating for Organogenesis Hldgs (NASDAQ: ORGO) was provided by Morgan Stanley, and Organogenesis Hldgs maintained their equal-weight rating.
Organogenesis Hldgs（納斯達克股票代碼：ORGO）的最新分析師評級由摩根士丹利提供，Organogenesis Hldgs維持同等權重評級。
When is the next analyst rating going to be posted or updated for Organogenesis Hldgs (ORGO)?
Organogenesis Hldgs（ORGO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organogenesis Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organogenesis Hldgs was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Organogenesis Hldgs的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Organogenesis Hldgs的最新評級是在2023年11月14日發佈的，因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating Organogenesis Hldgs (ORGO) correct?
分析師對 Organogenesis Hldgs (ORGO) 的評級正確嗎？
While ratings are subjective and will change, the latest Organogenesis Hldgs (ORGO) rating was a maintained with a price target of $3.00 to $3.50. The current price Organogenesis Hldgs (ORGO) is trading at is $2.35, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Organogenesis Hldgs（ORGO）評級維持不變，目標股價爲3.00美元至3.50美元。Organogenesis Hldgs（ORGO）目前的交易價格爲2.35美元，超出了分析師的預期區間。
